newsfilter
← Latest News
GlobeNewswire·

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PYPD
  • PolyPid Ltd. will present new pharmacokinetic data from the Phase 3 SHIELD II trial for D-PLEX₁₀₀ at the ESCMID Global 2026 congress in Munich, Germany, from April 17-21, 2026.
  • The abstract titled "Pharmacokinetics of local extended-release incisional doxycycline in patients undergoing abdominal colorectal surgery from the SHIELD II Phase 3 clinical trial" was co-authored by Prof. Antonino Spinelli & PolyPid.
  • Key findings show doxycycline concentrations remained detectable for up to 763 hours (approx. 32 days) with no burst release following local application of D-PLEX₁₀₀.
  • Plasma doxycycline levels stayed below 100 ng/mL, indicating minimal systemic exposure compared to oral administration levels that are 16 to 26 times higher.
  • CEO Dikla Czaczkes Akselbrad stated the results support D-PLEX₁₀₀'s mechanism of delivering sustained antibiotic exposure for 30 days directly at the surgical incision site.
  • The poster presentation (#P2740) will be given by VP Clinical Affairs Eyal Shoshani in Session 05b on Sunday, April 19, 2026, from 12:00 – 13:30 CEST in Poster Hall B3.
  • D-PLEX₁₀₀ uses PolyPid's Kynatrix delivery technology to provide prolonged local release of doxycycline for SSI prevention & has received FDA Breakthrough Therapy designation.
  • The SHIELD II trial demonstrated a statistically significant 60% relative risk reduction in SSI incidence for patients undergoing abdominal colorectal surgery with large incisions.
  • PolyPid is an innovative biopharmaceutical company listed on NASDAQ (PYPD) focused on long-acting, controlled-release drugs for surgical care & other medical needs.